Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

Abstract

Huntington's disease is a fatal neurodegenerative disorder caused by an expanded polyglutamine repeat in huntingtin (HTT) protein. We previously showed that calorie restriction ameliorated Huntington's disease pathogenesis and slowed disease progression in mice that model Huntington's disease (Huntington's disease mice)1. We now report that overexpression of sirtuin 1 (Sirt1), a mediator of the beneficial metabolic effects of calorie restriction, protects neurons against mutant HTT toxicity, whereas reduction of Sirt1 exacerbates mutant HTT toxicity. Overexpression of Sirt1 improves motor function, reduces brain atrophy and attenuates mutant-HTT–mediated metabolic abnormalities in Huntington's disease mice. Further mechanistic studies suggested that Sirt1 prevents the mutant-HTT–induced decline in brain-derived neurotrophic factor (BDNF) concentrations and the signaling of its receptor, TrkB, and restores dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP32) concentrations in the striatum. Sirt1 deacetylase activity is required for Sirt1-mediated neuroprotection in Huntington's disease cell models. Notably, we show that mutant HTT interacts with Sirt1 and inhibits Sirt1 deacetylase activity, which results in hyperacetylation of Sirt1 substrates such as forkhead box O3A (Foxo3a), thereby inhibiting its pro-survival function. Overexpression of Sirt1 counteracts the mutant-HTT–induced deacetylase deficit, enhances the deacetylation of Foxo3a and facilitates cell survival. These findings show a neuroprotective role for Sirt1 in mammalian Huntington's disease models and open new avenues for the development of neuroprotective strategies in Huntington's disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Sirt1 improves the motor function and attenuates brain atrophy in N171-82Q Huntington's disease mice and in BACHD mice.
Figure 2: Sirt1 preserves DARPP32 concentrations in the striatum, restores BDNF concentration and facilitates TrkB activation in Huntington's disease models.
Figure 3: Ablation of endogenous Sirt1 exacerbates mutant HTT toxicity, and the deacetylase activity of Sirt1 is required for its neuroprotection in a cell model of Huntington's disease.
Figure 4: Sirt1 counteracts mutant-HTT–induced hyperacetylation of Foxo3a and p53 and protects cells against mutant-HTT–mediated energy deficits in both mouse and cell models of Huntington's disease.

Similar content being viewed by others

References

  1. Duan, W. et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. USA 100, 2911–2916 (2003).

    Article  CAS  Google Scholar 

  2. Ross, C.A. & Thompson, L.M. Transcription meets metabolism in neurodegeneration. Nat. Med. 12, 1239–1241 (2006).

    Article  CAS  Google Scholar 

  3. McGill, J.K. & Beal, M.F. PGC-1α, a new therapeutic target in Huntington's disease? Cell 127, 465–468 (2006).

    Article  CAS  Google Scholar 

  4. Browne, S.E. & Beal, M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 8, 2061–2073 (2006).

    Article  CAS  Google Scholar 

  5. Haigis, M.C. & Sinclair, D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253–295 (2010).

    Article  CAS  Google Scholar 

  6. de Oliveira, R.M., Pais, T.F. & Outeiro, T.F. Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug Targets 11, 1270–1280 (2010).

    Article  Google Scholar 

  7. Parker, J.A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37, 349–350 (2005).

    Article  CAS  Google Scholar 

  8. Pallos, J. et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767–3775 (2008).

    Article  CAS  Google Scholar 

  9. Satoh, A. et al. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J. Neurosci. 30, 10220–10232 (2010).

    Article  CAS  Google Scholar 

  10. Schilling, G. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397–407 (1999).

    Article  CAS  Google Scholar 

  11. Zhang, J. et al. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 49, 2340–2351 (2010).

    Article  Google Scholar 

  12. Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182–6195 (2008).

    Article  CAS  Google Scholar 

  13. Menalled, L. et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319–336 (2009).

    Article  CAS  Google Scholar 

  14. Li, M., Huang, Y., Ma, A.A., Lin, E. & Diamond, M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 36, 413–420 (2009).

    Article  CAS  Google Scholar 

  15. Chopra, V. et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2–8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 104, 16685–16689 (2007).

    Article  CAS  Google Scholar 

  16. Chou, S.Y. et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93, 310–320 (2005).

    Article  CAS  Google Scholar 

  17. Simmons, D.A., Mehta, R.A., Lauterborn, J.C., Gall, C.M. & Lynch, G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol. Dis. 41, 436–444 (2011).

    Article  CAS  Google Scholar 

  18. Jeong, H. et al. Sirt1 mediates neurprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. advance online publication, doi:10.1038/nm.2558 (18 December 2011).

  19. Cohen, E. & Dillin, A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci. 9, 759–767 (2008).

    Article  CAS  Google Scholar 

  20. Bibb, J.A. et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA 97, 6809–6814 (2000).

    Article  CAS  Google Scholar 

  21. Greengard, P., Allen, P.B. & Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435–447 (1999).

    Article  CAS  Google Scholar 

  22. Fienberg, A.A. et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281, 838–842 (1998).

    Article  CAS  Google Scholar 

  23. Vonsattel, J.P. et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559–577 (1985).

    Article  CAS  Google Scholar 

  24. de la Monte, S.M., Vonsattel, J.P. & Richardson, E.P. Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47, 516–525 (1988).

    Article  CAS  Google Scholar 

  25. Zuccato, C. & Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311–322 (2009).

    Article  CAS  Google Scholar 

  26. Nakagawa, T. et al. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab. Res. Rev. 18, 185–191 (2002).

    Article  CAS  Google Scholar 

  27. Ivkovic, S., Polonskaia, O., Farinas, I. & Ehrlich, M.E. Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience 79, 509–516 (1997).

    Article  CAS  Google Scholar 

  28. Wang, W. et al. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 20, 500–508 (2005).

    Article  CAS  Google Scholar 

  29. Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179 (2007).

    Article  CAS  Google Scholar 

  30. Rodgers, J.T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113–118 (2005).

    Article  CAS  Google Scholar 

  31. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137–148 (2001).

    Article  CAS  Google Scholar 

  32. Morris, B.J. A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. J. Hypertens. 23, 1285–1309 (2005).

    Article  CAS  Google Scholar 

  33. Kops, G.J. et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316–321 (2002).

    Article  CAS  Google Scholar 

  34. Peng, K. et al. Knockdown of FoxO3a induces increased neuronal apoptosis during embryonic development in zebrafish. Neurosci. Lett. 484, 98–103 (2010).

    Article  CAS  Google Scholar 

  35. Mojsilovic-Petrovic, J. et al. FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J. Neurosci. 29, 8236–8247 (2009).

    Article  CAS  Google Scholar 

  36. Cui, L. et al. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69 (2006).

    Article  CAS  Google Scholar 

  37. Chaturvedi, R.K. et al. Impairment of PGC-1α expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet. 19, 3190–3205 (2010).

    Article  CAS  Google Scholar 

  38. Weydt, P. et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab. 4, 349–362 (2006).

    Article  CAS  Google Scholar 

  39. Tran, H. et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530–534 (2002).

    Article  CAS  Google Scholar 

  40. Puigserver, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction. Nature 423, 550–555 (2003).

    Article  CAS  Google Scholar 

  41. Milne, J.C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank L. Tsai at Massachusetts Institute of Technology for providing Sirt1 and H363Y retrovirus constructs, S. Imai at Washington University for providing Sir2 complementary DNAs (cDNAs), M. Macdonald at Harvard Medical School for providing STHdhQ7/Q7 and STHdhQ111/Q111 cells, S. Li and X. Li at Emory University for providing antibodies to EM48 and E. Waldron, C. Berlinicke, Y. Cheng and J. Jin at Johns Hopkins University School of Medicine for their technical assistance. This work was supported by the Hereditary Disease Foundation (W.D.), CHDI Foundation grant A-2120 (W.D.), NIH grant NS 16375 (C.A.R.), NIH grant NS35902 (D.M.H.), the NIA Intramural Research Program (B.M., H.C., S. Maudesley and M.P.M.), NIH grant R01NS051303 (D.K.), NIH grant EB003543 and ES012665 (S. Mori) and NIH grant NS065306 (J.Z.).

Author information

Authors and Affiliations

Authors

Contributions

M.J. designed and conducted the experiments and interpreted the data. J.W. designed and conducted the experiments in BACHD mice. J.F. contributed to the cell culture experiments. L.D. and R.H.C. performed the HPLC assays. H.-K.J. and D.K. provided the acetylated-lysine antibody and conducted the Sirt1 deacetylase assay. T.W. and D.M.H. provided the Sirt1 mice and the Sirt1 tissue expression data. H.C. contributed to the immunohistochemistry. L.X. and Q.P. conducted behavioral tests. Z.H., J.Z. and S. Mori performed the MRI scans. T.S. and R.L.-C. contributed to the BDNF assays. N.A. carried out the primary neuronal assay. S.Z., K.S. and J.Q. contributed to the coimmunoprecipitation, cell counting and immunohistochemistry. K.L.K.T., S.A., T.H.M., B.M., S. Maudsley and M.P.M. contributed to the metabolic measurements and discussion. X.W.Y. provided the BACHD mice. C.A.R. helped with the conception, design and interpretation of the experiments. D.K. contributed to the discussion and helped with the writing of the paper. W.D. designed, directed and coordinated the project and wrote the paper.

Corresponding author

Correspondence to Wenzhen Duan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–7 and Supplementary Methods (PDF 940 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, M., Wang, J., Fu, J. et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 18, 153–158 (2012). https://doi.org/10.1038/nm.2558

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2558

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing